Information for healthcare professionals about diabetic macular oedema.

Diabetic macular oedema (DMO) is a complication of diabetes that occurs when there is damage to the blood-retinal barrier, leading to accumulation of fluid within the intraretinal layers of the macular.1

Hyperglycaemia caused by uncontrolled diabetes can, over time, lead to serious damage to body systems, particularly nerves and blood vessels.2

Worldwide, diabetes is one of the leading causes of2:

 

 Icons depicting the heart, eye, kidneys and feet

 

Heart attack and stroke

 Icons depicting the heart, eye, kidneys and feet

 

Blindness

 Icons depicting the heart, eye, kidneys and feet

 

Kidney failure

 Icons depicting the feet

 

Lower-limb amputation

 

DMO is a complication of diabetic retinopathy. It can occur at any stage of diabetic retinopathy, although it is more likely to occur the longer the disease goes on.3

Approximately 7% of people with diabetes have DMO.4

 

Pie chart showing the proportion of diabetes spending on complications and treatment

 

Pie chart showing the proportion of diabetes spending on complications and treatment

 

Adapted from Diabetes UK.5

Of the £9.8 billion total cost of diabetes to the NHS, around 80% is spent on complications of disease.5

*This data analysis is from 2010/2011.5

Resources

  1. Bhagat N et al. Surv Ophthalmol 2009;54(1):1–320.
  2. World Health Organization. Diabetes. 2020. Available at: https://www.who.int/news-room/fact-sheets/detail/diabetes [Accessed September 2020].
  3. National Eye Institute. Macular edema. Available at: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/macular-edema [Accessed September 2020].
  4. Minassian DC et al. Br J Ophthalmol 2012;96(3):345–349.
  5. Diabetes UK. The Cost of Diabetes. Available at: https://www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf [Accessed September 2020].

OPT20-E023b September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]